AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment

Abstract

Hypertension is one of the most prevalent cardiovascular disorders worldwide, affecting 1.13 billion people, or 14% of the global population. Hypertension is the single biggest risk factor for cerebrovascular dysfunction. According to the American Heart Association, high blood pressure (BP), especially in middle-aged individuals (~ 40 to 60 years old), is associated with an increased risk of dementia, later in life. Alzheimer’s disease and cerebrovascular disease are the two leading causes of dementia, accounting for around 80% of the total cases and usually combining mixed pathologies from both. Little is known regarding how hypertension affects cognitive function, so the impact of its treatment on cognitive impairment has been difficult to assess. The brain renin-angiotensin system (RAS) is essential for BP regulation and overactivity of this system has been established to precede the development and maintenance of hypertension. Angiotensin II (Ang-II), the main peptide within this system, induces vasoconstriction and impairs neuro-vascular coupling by acting on brain Ang-II type 1 receptors (AT₁R). In this review, we systemically analyzed the association between RAS and biological mechanisms of cognitive impairment, from the perspective of AT₁R located in the central nervous system. Additionally, the possible contribution of brain AT₁R to global cognition decline in COVID-19 cases will be discussed as well.

Introduction

Decline in certain cognitive abilities is part of the process of normal aging, it includes reduced speed of acquiring new information and more difficulties in extracting recent memory. During aging, with some pathological conditions, the cognitive function could further decline, thus develop into mild cognitive impairment or dementia. On one hand, mild cognitive impairment is usually triggered during the early stages of dementia, and shares the same risk factors, including aging, genetic causes, and cardiovascular diseases. On the other, dementia is defined as a brain disease that manifests long-term and gradual loss of cognitive abilities, the symptoms of which are much more severe, and with no ideal treatment in most cases. The number of patients suffering from cognitive impairment is estimated to triplicate by 2050 as a result of aging of the world population and lack of disease-modifying treatments [1–4].

The most common type of dementia is Alzheimer’s disease (AD), whose etiology is actually still unclear. It has been believed, since quite a long time, that AD is caused by abnormal deposits of protein in brain, such as amyloid β (Aβ) and Tau, which are toxic to the neurons located in cognition-functioning areas. This well-known theory has been recently challenged more than ever, due to the unsatisfactory outcomes of the medications targeting amyloid in clinical trials [5]. One third of elderly people who have amyloid deposits in their brains are reported to have intact cognitive function [6]. In some cases, the impairment of neuronal function itself, has been considered as a possible etiology of AD [5]. Cerebrovascular dysfunction is another leading cause of dementia, involving vascular contribution to cognitive impairment and dementia. Together with AD, they account for around 80% of the total cases and usually combine mixed pathologies from each other [1]. In the last 2 decades, numerous studies have linked cardio- and cerebro-vascular risk factors to AD [7]. As a result, the roles of hypertension, diabetes, and dyslipidemia in the progression of AD have drawn more attention than ever. Notably, therapeutic strategies that target hypertension have been found to exhibit protective effects on cognitive function and ability to decrease the incidents of AD [8]. Commonly used anti-hypertensive drugs include thiazide diuretics, calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II (Ang-II) receptor blockers (ARB), and beta blockers (BB). Among all categories, drugs that directly target the renin-angiotensin system (RAS), such as ACEI and ARB, have shown more consistent and promising ability to preserve cognitive function, and to reduce AD-associated pathological alterations in both preclinical and clinical trials [9–11].

The RAS regulates fluid and electrolyte balance, as well as systemic vascular resistance. Beyond its many roles in maintaining homeostasis, the RAS is an essential regulator of blood pressure (BP) [12]. Upon decrease in renal blood flow, renin is generated by hydrolysis of its precursor-prorenin, then directly released into the circulation. In the presence of renin, angiotensinogen is converted into angiotensin I (Ang-I), and subsequently into Ang-II by the action of angiotensin-converting enzyme (ACE). Ang-II is a potent vasoconstrictive peptide and the main effector of the RAS, acting through its dominant receptor, Ang-II type 1 receptor (AT₁R). Overactivation of the RAS has been proved to be involved in the development of multiple cardiovascular diseases and metabolic disorders, such as hypertension, heart failure, atherosclerosis, obesity, and diabetes [13, 14], many of which have been identified as risk factors for cognitive impairment. It has been shown that Ang-II impairs neuro-vascular coupling and cognitive function independently of its pressor response, highlighting the deleterious effect of RAS overactivation on memory [15]. Neuro-vascular coupling, also known as functional hyperemia, represents alterations in local perfusion that take place in response to changes in neuronal activity, thereby functioning as the basic unit of cerebral blood flow regulation. Compromised neuro-vascular coupling is also embedded in AD, where activated RAS is involved too [16]. A pathological study based of AD patients’ brains showed significant immuno-reactivities for ACE and Ang-II surrounding the vasculature in the cerebral cortex [17]. In addition to vessels, immuno-reactivities of ACE and Ang-II were also found to be higher in AD patients’ cortical neurons, suggesting that RAS may have a direct impact on neuronal functions as well.

Thereby in this review, the possible roles of brain AT₁R, especially those neuronal residents, in the development of cognitive impairment will be summarized and discussed. In addition, recent related updates, including possible contribution to global cognition decline in Coronavirus Disease 2019 (COVID-19) cases will be discussed.

The Science of Angiotensin Receptors in Cognitive Impairment

In addition to the systemic RAS, there is also believed to have tissue specific expression and regulation of the RAS. Locally expressed RAS components have been found within multiple organs, including the kidneys, adrenal glands, adipose tissue, cardiovascular system, as well as brain, and have a variety of physiological or pathophysiological functions in association or independently of the systemic RAS [18]. Although it is still a controversial topic, there is growing body of evidence demonstrating the existence and pivotal functions of brain-specific RAS, which contains brain-locally expressed angiotensinogen, renin, (Pro)renin receptor, ACE, angiotensin-converting enzyme type 2 (ACE2)/angiotensin-(1-7) [Ang-(1-7)]/Mas axis, and most members of angiotensin receptors [19]. So far, three types of angiotensin receptors have been reported, and they are type 1, 2, and 4, with Ang-II or Ang-IV as their ligands. Notably, it has to be clarified that rodents express two AT₁R subtypes, AT_1aR and AT_1bR; and within the brain, neurons are positive for both subtypes, while glia only contains AT_1bR [20]. In brain vasculature, AT₁R is responsible for the impairment of endothelial function and neuro-vascular coupling [15, 21, 22], through increasing oxidative stress. Similar to ACE, AT₁R is also expressed in areas that are critical to learning and formation of memory [23], however, their direct role in the development of cognitive impairment is still unclear and quite debatable. As to the type 2 receptors, their expression is more plentiful in fetal tissues, and the ratio of AT₂R and AT₁R drops dramatically after birth, according to related autoradiographic studies [24]. Because AT₂R and AT₁R are coupled with different types of G protein, for AT₂R is inhibitory G proteins (Gi), their effects are quite opposite (as shown in Fig. 1). In general, AT₂R-mediated actions counter most of the effects induced by AT₁R activation, including anti-proliferation, anti-inflammation, and vasodilation [25]. Therefore, AT₂R-mediated signaling is considered to be neuroprotective. Selectively knocking down AT₂R leads to impairments in spatial memory and exploratory behavior [26], while direct stimulation of AT₂R by C21, effectively prevents post stroke cognitive impairment in aged animals [27]. However, considering that the affinity of Ang-II to AT₁R is significantly higher, the effects of Ang-II/AT₂R-mediated signaling are often masked, especially when the expression of AT₁R is up-regulated under certain circumstances, such as cerebral ischemic injury and hypertension [28, 29]. In mice with AD-related mutations of human amyloid precursor protein (APP), C21 showed no significant improvement in memory, suggesting that AT₂R might not be an ideal therapeutic target for APP-related cognitive and cerebrovascular deficits [30]. As to “AT₄R”, it is actually considered as a binding site for Ang-IV and its existence is still controversial. There are recent studies reporting that Ang-IV/AT₄R signaling is able to rescue cerebrovascular dysfunction and cognitive impairment in AD models, suggesting a potential new target for treatment of cognitive decline [31, 32]. Interestingly, in a study simultaneously targeting AT₄R and AT₁R, divalinal (selective AT₄R blocker) countered losartan’s ability to rescue spatial learning and memory in APP mutated mice, suggesting that the beneficial effects of ARB on cognitive function could be resulting from the unmasked Ang-IV/AT₄R signaling [31, 33].

Fig. 1.

The science of renin-angiotensin system in hypertension and cognitive impairment. Through different signaling pathways, Ang-II leads to specific effects on blood pressure (BP) regulation and hypertension-associated cognitive impairment. In general, Ang-II/AT₁R pathway induces deleterious impact on cognitive function, promoting cognitive impairment, while the others exhibit protective effects at different levels

Regulatory RAS, the Yin of Y-Ang-II

In addition to its classic arm, the RAS is also composed of compensatory mechanisms preventing it from overactivation. By removing one amino acid, ACE2 transforms Ang-II into Ang-(1-7), thus turning the vasoconstrictor into a vasodilator peptide. As a major component of the regulatory RAS, Ang-(1-7) counters most of the effects of Ang-II, leading to nitric oxide (NO) release, reduction of oxidative stress, and preservation of baroreflex and autonomic balance. More recently, Ang-(1-7) has been found to protect against brain damage in related neurological disorders, such as brain ischemia, traumatic brain injury, and AD, with remarkable inhibition of microglial activation, reduction of inflammatory response, and protection of neurons from apoptosis [34–36]. Importantly, in the case of AD, the enzymatic activity of ACE2 in brain was found to be markedly reduced and associated with increases in Aβ and tau pathology. Unlike cortical ACE2, the activity of ACE2 in the cerebrospinal fluid of AD patients was increased, suggesting the reduction of tissue-bound ACE2 could be result from ectodomain shedding [37, 38]. The mechanism of ACE2 impairment during AD is still unknown, besides ubiquitination, the activity of membrane-bound ACE2 can also be decreased via a disintegrin and metalloprotease 17 (ADAM17)-mediated shedding. Within the central nervous system (CNS), ACE2 protein is mostly observed in the cell body of neurons. Our previous work shows that the enzymatic activity of ACE2 in cortical neurons is significantly decreased by the treatment with high glutamate concentrations, suggesting that excitotoxicity could impair the compensatory activity of ACE2 [39]. This glutamate-induced reduction of ACE2 activity was then demonstrated to be mediated through ADAM17, which reacts to oxidative stress and p38-mitogen-activated protein kinase (MAPK) pathway. Together with the Ca²⁺ influx via ionotropic glutamate receptors, all of those factors are within the typical signaling flows of excitotoxicity during AD.

Possible Roles of AT₁R in Etiology of Cognitive Impairment

Ang-II/AT₁R-mediated signaling impairs cognitive function independently of its pressor effect. Outside of the brain nuclei involved in cardiovascular regulation, AT₁R is also expressed in various cell types within regions responsible for learning and memory, such as amygdala, hippocampus, and multiple cortical areas [23, 40–42]. Previous pre-clinical studies have demonstrated a significant neuroprotective effect of ARB on neuronal injury, decline of neurological performance, and cognitive loss [43]. Regarding Ang-II/AT₁R signaling, there are several mechanisms should be considered in the etiology of cognitive impairment (Fig. 2).

Fig. 2.

Schematic illustration of how brain AT₁R promotes neurodegeneration and cognitive impairment. Neurodegeneration and vascular dysfunction are not independent of each other. For one thing, they share similar signaling pathways, as shown in the yellow bubble. For another, during hypertension, vascular dysfunction could be a key trigger for neurodegeneration, while changed acetylcholine (Ach) tone and neuronal activity would further compromise the functional hyperemia Possible roles of AT1R in etiology of cognitive impairment

AT₁R and Oxidative Stress

Increased oxidative stress in brain has been considered as an early feature of AD, and contributes to its pathogenesis [44]. Via AT₁R, Ang-II evokes reactive oxygen species (ROS) production by NADPH oxidase (NOX), mitochondrial dysfunction, and reduction of endogenous antioxidant enzymes. That is to say, when Ang-II/AT₁R signaling is upregulated during AD progression, it can increase oxidative stress and further deteriorate related pathological alterations in brain. In Tg2576 mice, NOX2-dependent pathways and ROS production in perivascular macrophages (PVM) were found to contribute to AD-associated cerebrovascular dysfunction [16]. In another study from the same group, the authors identified that AT₁R located in PVM are responsible for increased production of ROS [15], thus promoting cerebrovascular dysfunction and cognitive impairment in mice with Ang-II-induced hypertension. In vascular adventitial fibroblasts, Ang-II decreased both the expression and activity of catalase, and further investigation revealed that Ang-II/AT₁R-induced activation of ERK1/2 (extracellular-signal regulated kinase) pathway is involved in the downregulation of this endogenous antioxidant enzyme [45]. Beyond the vessels, in Neuro2A neuronal cells, Ang-II was also reported to downregulate the expression of Nrf2 (nuclear factor erythroid 2-related factor 2), a key regulator of the endogenous anti-oxidative response [46]. Reduced Nrf2 protein level is also associated with AD, as recent studies have shown significant therapeutic influence of Nrf2 activators on AD pathology both in vitro and in vivo [47]. Ang-II-mediated signaling pathway has been shown to be related to mitochondrial dysfunction and mitochondria-produced ROS in the neurons of rostral ventrolateral medulla (RVLM), by damaging the electron transport chain complexes [48]. In SH-SY5Y neuronal cells, Ang-II treatment was also found to induce aberrant mitochondrial fission, through protein kinase C (PKC) δ activation [49]. Moreover, Ang-II/AT₁R signaling can affect NO production and bioavailability through mechanisms involving ACE2/Ang-(1-7) and AT₂R, which have been partially discussed in the previous section. Notably, in the CNS, Ang-II induces both ACE2 internalization and ADAM17-mediated ACE2 shedding via AT₁R; therefore, compromising the compensatory activity of ACE2 and promoting RAS overactivation [29, 50]. In such case, AT₁R-mediated signaling in brain could facilitate cognitive impairment and deteriorate AD-related pathology by exacerbating oxidative stress that triggers neurodegeneration and neuronal apoptosis. According to a recent study, NO deficit in cerebral endothelial cells can reduce neuronal calpain nitrosylation and lead to tau phosphorylation by activating cyclin-dependent kinase 5 [51]. This might explain how central Ang-II administration induced Alzheimer-like tau phosphorylation in normal rat brains [52].

AT₁R and Neuroinflammation

A growing body of literature has proposed brain inflammation as a driving force or causative factor of neuro-degradation [53]. In the brain of AD and vascular dementia, cytokines and inflammatory mediators, such as tumor necrosis factor α (TNFα), interleukin (IL)-1α, IL-1β, IL-6, cyclooxygenase (COX)-2, and nuclear factor (NF)-κB, are among the genes that are markedly upregulated [54]. Meanwhile, gliosis, represented by massively activated/increased astrocytes and microglia, is considered to be one of the hallmarks of AD progression [55]. Ang-II has been known to evoke pro-inflammatory responses in various brain cell types, especially in the vasculature and glial cells. In brain vessels, Ang-II promotes inflammation not only through activation of NF-κB-mediated genes, but also by suppression of peroxisome proliferator-activated receptors (PPAR) [56]. Therefore, Ang-II/AT₁R signaling is able to stimulate NLRP3 inflammasome activation and increase the activity of caspase-1 and -3, thus promoting the release of pro-inflammatory cytokines [57]. Taking advantage of a novel transgenic mouse model, we previously showed that neuronal AT₁R plays a vital role in the development of neuro-inflammation, by demonstrating its regulation of ADAM17 activation [29]. Besides ACE2, various inflammatory cytokines, chemokines, and adhesion molecules are the substrates of ADAM17, including TNFα, ICAM-1 (intercellular adhesion molecule 1), VCAM-1 (vascular adhesion molecule 1), and CX3CL1 (also known as Fractalkine) [58]. In deoxycorticosterone acetate (DOCA)-salt hypertension, the activity of ADAM17 is solely determined by AT₁R-mediated signaling, which involves ROS and downstream MAPK signaling pathway (both ERK1/2 and p38-MAPK). In the same study, evidence of neuronal AT₁R in modulating neuron-microglia communication was also provided. In FACS-sorted hypothalamic cells, DOCA-salt treatment significantly and selectively up-regulated the mRNA level of TNFα in non-neuron/non-astrocyte cells, while such alteration was not observed in mice with neuronal AT₁R deficiency [29]. ADAM17 is considered as a player in the modulation of neuron-microglia communication, through shedding of ectodomains of ACE2 and CX3CL1. As mentioned earlier, the enzymatic activity of ACE2 is critical to the endogenous production of Ang-(1-7), which has direct inhibitory effect on microglia activation and related pro-inflammatory responses [59]. In addition, ADAM17 also cleaves the membrane-bound CX3CL1, a ‘turn off’ signal from neuron to microglia [60, 61], and increase the release of TNFα and IL-1β from microglia through soluble CX3CL1.

Does microglia express AT₁R? The answer is controversial. It has been reported that microglial AT₁R can cross-talk with TLR4 (Toll-like receptor 4) and facilitate ROS production in the hypothalamic paraventricular nucleus (PVN) [62]. However, there is no evidence so far showing that Ang-II activates microglia through directly acting on microglial AT₁R, further investigations are certainly required to understand the role of microglial Ang-II/AT₁R-induced pro-inflammatory response. As to astrocytes, the role of their AT₁R is also underdeveloped. It is known that astrocytes actively participate in synaptic transmission and plasticity due to their essential role in glutamate turnover [63]. Recently, the role of astrocytes in CNS inflammation has been stepping into the spotlight. Multiple pro-inflammatory pathways have been associated with reactive astrocytes within the brain, including both cytokines and damage-associated molecular patterns [64]. In normal conditions, astrocytes express very few AT₁R, while these receptors can be markedly up-regulated upon Ang-II stimulation [65, 66]. However, the specific role of AT₁R expressed on astrocytes in the progression of CNS inflammation is still a question waiting for its answer. In a mouse model of multiple sclerosis, Ang-II/AT₁R signaling is found to affect astrocytes by inducing cytokines release, such as tumor growth factor β (TGFβ) [67]. In the brains of hypertensive rats, treatments with ARB attenuated the hypertension-related astrocyte activation and neuroinflammation, by activating Wnt/β-catenin signaling [68]. But without manipulations specific to AT₁R on astrocytes, it is still unclear whether Ang-II/AT₁R signaling is responsible for the activation of astrocytes during pathological states. Selective ablation of astrocytic AT₁R was found to attenuate sympatho-excitation as well, in a heart failure mouse model induced by myocardial infarction [65]. It was reported earlier that Ang-II inhibited glutamate transporter function via astrocytic AT₁R, thereby increasing extracellular glutamate levels, which could support the activation of pre-sympathetic glutamatergic neurons and sympatho-excitation [69]. Later on, we identified the indispensable role of neuronal AT₁R to the activation of pre-sympathetic glutamatergic neurons. Using selective deletion of AT₁R on glutamatergic neurons, kidney-related pre-sympathetic glutamatergic neurons were no longer able to depolarize upon Ang-II stimulation, when compared to neurons with an intact neuronal AT₁R signaling pathway [28].

AT₁R and Neurodegeneration

Immuno-reactivity for ACE and Ang-II was found to be higher in cortical neurons of AD patients, suggesting that the RAS might support cognitive impairment directly through neuronal mechanisms [17]. Acute application of Ang-II can excite hippocampal CA1 neurons by abolishing incoming GABAergic inhibition [70]. However, this is considered as an anxiolytic effect, and exhibits no ability to enhance memory or reverse memory deficits. In rodents’ hippocampal slices, the administration of Ang-II was found to impair the induction of LTP (long-term potentiation) in the dentate gyrus, which is critical to spatial memory (or memory discrimination), and this effect can be blocked by losartan, an AT₁R antagonist [42, 71]. In addition, Ang-II/AT₁R signaling also suppresses LTP induction and LTD (long-term depression) stabilization in the lateral nucleus of the amygdala from rat brain slices [72, 73]. Both LTP and LTD are associated with the activity of synaptic transmission, in which the involvement of Ang-II/AT₁R signaling highlights its impact on synaptic plasticity and cognitive functions. A more recent study reported that hippocampal p38-MAPK pathway is critical to the inhibition of LTP in Ang-II-dependent hypertensive mice [74], indicating again that the AT₁R can impinge hippocampal neuronal function and memory through its downstream signaling.

Phosphatidylinositol-4,5-bisphosphate (PIP₂), an important membrane phosphatidylinositol lipid, plays a critical role in maintaining normal synaptic transmission [75]. Blocking PIP₂ recruitment can induce a significant inhibition in LTP, and mimic aging-related memory loss [76]. Notably, a significant reduction of PIP₂ level in cortex has been associated with AD progression [77]. Phosphatidylinositol 4-kinase (PI4K) is one of the key enzymes for PIP₂ bio-synthesis, and its activity was also found to be decreased, by ~ 50%, in the cortex of AD patients [78]. However, PI4K activity might not be significantly affected by aging, as supported by an enzymatic study in old rats [79], suggesting that reduced PI4K activity could be a hallmark for neurodegenerative disorders. It has been well-known that PIP₂ is a second messenger downstream of G_q protein-coupled receptors, including AT₁R. In cardiomyocytes, the activity of PI4K can be upregulated by Ang-II/AT₁R through PKCs [80], therefore the cellular content of PIP₂ increased following Ang-II treatment. However, the boost of PIP₂ re-synthesis could be limited, and more investigation is necessary to determine how chronic brain RAS activation could affect the activity of PI4K as well as PIP₂ turnover in neurons.

As mentioned earlier, AT₁R and AT₂R exhibit opposite effects from many perspectives. Unlike AT₂R, AT₁R activation supports cell proliferation and tissue growth [81]. Therefore, it is not surprising that Ang-II treatment can induce expression of brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of growth factors [82, 83]. High salt diet induces the activation of vasopressin neurons and hypertension via BDNF, while removal of BDNF significantly attenuates Ang-II-induced hypertension [84, 85]. From this perspective, it looks like Ang-II/AT₁R signaling could improve neuronal function through up-regulating BDNF. However, these findings relate to BDNF within regions that are predominantly responsible for cardiovascular regulation, but BDNF levels in cortical and hippocampal areas are actually downregulated in hypertension [86], suggesting that neurogenesis in those regions could be passively affected by brain RAS overactivation.

In addition to BDNF, Ang-II/AT₁R signaling is also involved in other mechanisms that contribute to neurodegenerative alterations. In the etiology of AD, one of the theories is that impairment of cholinergic signaling in the brain underlies the development of AD [87]. Lesion of cholinergic neurons or inhibiting cholinergic pathways, lead to impaired neuro-vascular coupling, due to the reduced neuronal activity (demonstrated by the lower gamma oscillations of local field potential), indicating the critical role of neuro-activation in neuro-vascular coupling and the importance of acetylcholine (ACh) tone [88]. Both synthesis and release of ACh are markedly reduced during AD, and replenishing ACh levels pharmacologically show therapeutic benefits on AD-related cognition decline [88]. In both human temporal cortex and rat entorhinal cortex, Ang-II was found to significantly decrease the release of ACh, and antagonizing its binding sites was able to abolish this inhibitory effect, indicating that brain RAS activation has a negative impact on cholinergic neurons [89, 90]. Interestingly, ADAM17 can be a double-edge sword in the progression of AD. On one hand, ADAM17 cleaves ACE2, TNFα, and CX3CL1, promoting the development of neuroinflammation. On the contrary, ADAM17 is an α-secretase, which degrades APP into soluble APP α fragment, helping to ameliorate neurotoxic Aβ deposition [91]. Since the muscarinic type 1 receptor is thought to lead the beneficial effect of ADAM17 [92, 93], this good side of ADAM17 could be masked when ACh tone is low, while Ang-II level is high.

AT₁R and Apoptosis

Although anti-proliferation is one of the roles of AT₂R-mediated signaling, it is AT₁R that participate in Ang-II-induced neuronal cell death. Ang-II was found to support the development of Parkinson’s disease by triggering apoptosis of dopaminergic neurons [94]. It was further revealed that the processes of autophagy and apoptosis induced by Ang-II treatment were the consequences of AT₁R activation [95]. Enhanced oxidative stress through NOXs is thought to be one of the mechanisms underlying Ang-II/AT₁R-induced neuronal apoptosis. Oxidative stress is able to damage all components within a living cell, including lipids, proteins, and DNA, and it is considered as a major contributor to neuronal loss during AD [44]. In hippocampal neural stem cells, Ang-II induces ROS production, which can be blocked by pre-treatment of losartan. ROS then activates AMPK (AMP‐activated protein kinase)-mediated apoptosis and autophagy signaling, eventually causing neuronal death [96]. Moreover, Ang-II/AT₁R signaling was found to trigger apoptosis in dopaminergic neurons by undermining mitochondria permeability, therefore, this mitochondria-dependent apoptotic pathway is considered as a separate mechanism from the ROS-induced apoptosis [97]. In addition to oxidative stress, enhanced pro-inflammatory response also supports the apoptotic effect of Ang-II on neurons. For example, increased release of pro-inflammatory cytokines, such as TNFα, activate NF-κb-mediated NLRP3 inflammasome, thus leading to the process of neuronal apoptosis [98, 99]. In INS-1 islet β-cells, Ang-II has been demonstrated to induce apoptosis by activating NLRP3 inflammasome via AT₁R [57]. Blocking AT₁R via ARB has been shown to provide an anti-apoptotic effect in various disease models and related cell types, and this could be one of many factors that support the therapeutic use of ARB in treating neurodegenerative alterations in AD.

AT₁R and BBB Disruption

The blood–brain barrier (BBB) is a tissue matrix located within the endothelium of cerebral capillaries and choroids plexus, controlling substances exchange between the CNS and periphery. Due to its protective role, the integrity of BBB is critical to the maintenance of a highly regulated brain internal homeostatic process. Compromised integrity of the BBB facilitates the entry of neurotoxic substances into the brain, and is often associated with increased inflammatory and immune responses [100]. In patients with early-stage AD, magnetic resonance imaging has showed global BBB leakage, which is associated with cognitive decline, highlighting the necessity of BBB integrity to normal cognitive function [101]. In a rat model of postoperative cognitive dysfunction, the laparotomy surgery was shown to increase Ang-II release in the hippocampus and impair BBB integrity via Ang-II/AT₁R-mediated signaling pathways [102]. While in spontaneously hypertensive rats, normalization of brain Ang-II levels could decrease BBB leakage and improve its function within the autonomic brain areas [103]. Treatment with Ang-II was found to increase the permeability of cultured BBB micro-vessel endothelial cells in a time-dependent manner, and this Ang-II-induced leakage could be prevented by telmisartan [104], demonstrating the contributory role of Ang-II/AT₁R signaling in the disruption of BBB integrity. A recent study reported that specific knockdown of cerebral endothelial AT₁R completely prevented BBB disruption in the Ang-II-induced hypertension model, indicating that AT₁R-mediated signaling in endothelial cells could initiate the BBB opening during the development of hypertension [22]. Moreover, HMGB-1 (high mobility group box 1), a possible downstream effector of Ang-II/AT₁R signaling, was found to be involved in BBB disruption as well. An in vitro study has revealed that HMGB-1 induced a significant and concentration-dependent increase of dextran leak-out from the BBB and pre-treatment with anti-HMGB-1 antibody exhibited positive effect on keeping the integrity of BBB [105]. Additionally, a marked increase of serum HMGB-1 was observed in AD patients and positively correlated with the patients’ Aβ levels [105], suggesting that HMGB-1-mediated BBB disruption could be considered as a biomarker for AD progression. Due to the damage induced by Ang-II/AT₁R signaling, the BBB disruption initiated by hypertension might contribute to the development of AD in late-life of hypertensive patients, and this could be one of the reasons why ARB exhibit the potential to reduce AD risk.

β-Arrestin-Biased AT₁R Signaling

After binding to AT₁R, Ang-II actually triggers multiple intracellular signaling pathways, in which the classic one is predominant due the excessive activation of Gα_q/11. Among the additional mechanisms of Ang-II/AT₁R signaling, AT₁R-mediated β-arrestin recruitment, with its subsequent desensitization and internalization of AT₁R, has gained significant attentions due to its potential as remedy for pathological manifestations involving an over-activated RAS [106]. β-Arrestins are ubiquitous scaffolding proteins that induce receptor desensitization, internalization, and other intracellular signaling mechanisms, so the β-arrestin-biased AT₁R signaling is able to counter most of the classic effects of Ang-II. Between the two subtypes of β-arrestin identified so far, β-arrestin 2, instead of β-arrestin 1, is the mediator of the Gα_q/11-independent responses during AT₁R activation [107]. Ligands able to selectively stimulate a specific pathway over the others are called biased agonists, and biased activation of AT₁R can be triggered by stretch or its biased agonists. So far, several biased agonists of AT₁R, most of which are Ang-II analogs, have been synthesized, such as [Sar¹, Ile⁴, Ile⁸]-Ang-II and TRV027 [106, 108]. TRV027 ([Sar¹, _D-Ala⁸]-Ang-II) serves as a β-arrestin-biased ligand of AT₁R and antagonizes the classic Gα_q/11 pathway of Ang-II/AT₁R. We have previously reported the beneficial effects of central administration of TRV027 on hypertension, autonomic, and vascular function, as well as its ACE2-preserving ability in neurons [108], suggesting a potential of AT₁R-biased agonists, especially TRV027, in treating hypertension-associated cognitive impairment and the vascular component of AD.

Sex Differences

The level of AT₁R expression is upregulated throughout the developmental stage, and should exhibit no sex-related preference, according to the nature of AT₁R gene. However, sex-specific modulation of BP, along with activity of the RAS, have been reported in various hypertension models. For example, mean arterial pressure rose faster in wildtype male than female mice after systemic Ang-II infusion, and this sex difference was found to be attenuated in mice with ACE2 deficiency [109]. Accordingly, it is possible that AT₁R-mediated signaling can be affected by the compensatory activity of ACE2. However, despite the fact that ACE2 gene is located on the X chromosome, it is still controversial whether females have more ACE2 expression or higher activity [110]. Moreover, using global ACE2 knockout mice, we detected higher mRNA levels of ADAM17 and Mas1 in the hypothalamus, but no significant change in AT₁R mRNA (unpublished data), suggesting that AT₁R might not be significantly affected by ACE2 expression under normal circumstances. Interestingly, lower mRNA expression of AT₁R and AT₁R to AT₂R ratio were detected in the aorta and mesenteric vessels of female mice, compared to males. Instead of ACE2, estrogen and its related signaling were considered to be a possible explanation [111]. Whether there is any difference in neuronal AT₁R abundance between males and females is still unclear, despite that expression of AT₁R in the vasculature does show sex differences. Prior to menopause, females are protected by their sex hormones, such as estrogen and the compensatory activity of ACE2. However, with aging and the loss of these protections, females are found to be more vulnerable to cardiovascular diseases, as well as to cognitive impairment. Since mid-life BP is considered to be critical to normal cognitive performance in late-life, it is important for women who are undergoing menopause to maintain adequate estrogen levels for protection from hypertensive stimuli.

An update on ARB in Clinical Trials

The association between hypertension and age-related cognitive impairment has now been accepted, and more recently, hypertension has also been linked to the development of AD [112]. Multiple clinical trials and meta-analysis have been performed to study whether anti-hypertensive medications show a beneficial effect on either treating dementia, including AD, or delaying its onset in the elderly [8–10]. Although ARB showed promising data in rodent models and in vitro, it is still controversial whether ARB have the ability to decrease AD risk in human, while CCB, ACEI, and diuretics were found to reach significant lower risk ratio, compared to 1 [8]. A recent study reported that treatment of losartan alone was not able to restore the functional hyperemia in hypertensive mice, and the treatment effect of losartan was found to be weaker than amlodipine, a CCB drug, closely aligning with clinical observations [113]. Possible reasons have been considered for this discrepancy between clinical trials and experimental models, with regards to the therapeutic potential of ARB in dementia. Due to the possible difficulties of ARB getting into the brain (related data are contradictory), there might not be enough amount of the active molecules reaching the neuro-vascular unit, where neuronal and peri-vascular AT₁R can be targeted; or cardiovascular nuclei, such as PVN and RVLM, where RAS promotes sympatho-excitation via neuronal AT₁R. As to the 3 other types of anti-hypertensive drugs, which were shown to significantly reduce AD incidents in the meta-analysis, they are thought to work effectively in the periphery as well, through reducing blood volume and disrupting the bio-synthesis of Ang-II in the circulation, unlike the ARB.

Possible Contribution of AT1R to COVID-19-Related Cognitive Dysfunction

As the major cell entry receptor for SARS-CoV-2, ACE2 has gained much attention since December 2019. As mentioned earlier in this review, ACE2 is a key player in the regulatory axis of the RAS. At the beginning of the pandemic, there was a debate regarding the role of RAS in both infection and progression of COVID-19, and whether its overactivation could prevent or promote SARS-CoV-2 infection. As more patients were diagnosed and hospitalized, an agreement has been reached, showing that RAS overactivation, or loss of ACE2 compensatory activity, would lead to more severe symptoms of infection, difficulties in recovery from the illness, and importantly worse outcomes [114, 115]. About 30–50% of the people hospitalized due to COVID-19 have hypertension and those hypertensive patients have a two-fold higher chance of dying from COVID-19 [116]. Treatments that target RAS, especially AT₁R, have already been used to prevent infection-related tissue damage [117]. Notably, it has been suggested that the entry of SARS-CoV-2 into the cells via ACE2 binding is actually AT₁R dependent [118]. In vitro, blocking AT₁R with losartan or β-arrestin-biased AT₁R ligand, TRV027, fully prevented the internalization of ACE2 activated by the binding of S1-spike protein [118]. In fact, TRV027 is currently under clinical trial to determine the role of RAS overactivation in COVID-19 infection, and recently announced data from 30 patients of the proof-of-concept study (COVRAS). The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints regarding the disease severity and progression of COVID-19 (https://www.trevena.com/investors/press-releases/detail/279/trevena-announces-results-of-trv027-proof-of-concept-study).

Beyond serious respiratory and cardiovascular symptoms, negative influence of SARS-CoV-2 infection has also been reported in the CNS [119]. One of the most common, important, and definitely infection-related symptoms in COVID-19 patients is the loss of smell and taste. With the continuous mutation of the virus, as well as more and more people being vaccinated, the symptoms of the COVID-19 are becoming lighter and less severe, nevertheless, loss of smell and taste is still being reported in most infected people, as shown in the CDC data. Some would even suggest that loss of smell and taste better predicts the disease than other well-known symptoms such as fever and cough [120]. Although the underlying mechanism is still not clear, it has been suggested that loss of olfactory receptor neurons and brain infiltration of the olfactory centers could be considered to explain the dysfunction of smell [121], implying that SARS-CoV-2 could infect the CNS through a “quiet” manner, instead of causing major inflammation. At the beginning of the pandemic, we have identified the expression of ACE2 protein in neurons of the human brain, highlighting the potential of SARS-CoV-2 for neuro-invasion [122]. In addition to olfactory dysfunction, it has also been found that patients with recent SARS-CoV-2 infection could experience global cognition decline, associated with memory, attention, and executive function, particularly verbal fluency [123]. Indeed, SARS-CoV-2 is able to invade human neurons in vivo. Using human brain organoids, mice expressing human ACE2, and autopsies from deceased COVID-19 patients, the neuro-invasive capacity of SARS-CoV-2 has been detected and further studied [124]. It has also been shown that the infection by SARS-CoV-2 of brain neurons in humans is: (1) ACE2 dependent, (2) would induce metabolic changes of the cell, and (3) would lead to local vascular alteration. Therefore, RAS in the brain, especially vascular and neuronal AT₁R, could be actively involved in the development of COVID-19-related cognitive impairment. Moreover, following the neuro-invasion and replication of the virus, compromised ACE2 compensatory activity resulting from the virus-associated internalization and the RAS overactivation, would be in favor of neuro-toxicity and neuro-inflammation, which could further contribute to the development of cognitive dysfunction in the COVID-19 patients (Fig. 3).

Fig. 3.

Possible contributions of brain AT₁R in COVID-19-related global cognition decline. SARS-CoV-2 is neuro-invasive and this might lead to the onset of COVID-19-related global cognition decline. The entry of SARS-CoV-2 into the cells via ACE2 binding requires AT₁R-mediated signaling, which has already been considered as a therapeutic target for treatment of COVID-19

Perspectives

The negative impact of RAS overactivation on cognitive impairment has now been accepted. Some argued that this was due to its pressor effect, and some suggested otherwise. In addition to the cognition-related neural circuits, neuro-vascular coupling, which is initiated by evoked neurons, is important in cognitive behavior as well. Therefore, the processes of learning and memory rely on neurons with normal activity and regulated activation, and a growing body of people start to consider that treating or reversing neurodegeneration is the key for the AD remedy. Accordingly, brain AT₁R, especially those located in neurons, and associated signaling pathways, should also be considered as potential therapeutic targets. This could open a new avenue for a better understanding and treatment of cognitive impairment.

Author Contributions

XC, RY, and JX conceived and completed the general structure of the review. HW, QS, SY, JW, and JX drafted the manuscript. HW and HG prepared the schematic figures. FL and JX critically revised the work.

Declarations

Conflict of interest

Authors declare that there is no conflict of interest.

Ethical Approval

Not applicable.

Consent to Participate

All authors reviewed and approved the manuscript for publication.

Data Availability

Not applicable.

Code Availability

Not applicable.